Jan Buckner, MD

Medical Oncologist

Conditions Treated

Asbestosis Laryngeal Cancer Lung Cancer Pericardial Mesothelioma Pleural Mesothelioma

specialties & services

Chemotherapy CT Scan MRI

Hospitals & Clinics

Mayo Clinic Rochester

Bio & Insurance Information

Dr. Jan Buckner is a medical oncologist in Rochester, Minnesota. He got his medical degree from University of North Carolina at Chapel Hill School of Medicine and did his residency at Spectrum Health-Butterworth Campus. Dr. Buckner went to Mayo School of Graduate Medical Education and obtained his fellowship in medical oncology. He is certified by the American board in both medical oncology and internal medicine. Dr. Buckner has over 20 years of experience and is currently affiliated with Mayo Clinic – Rochester.



Education & Training

University of North Carolina at Chapel Hill School of Medicine

Medical School

Spectrum Health-Butterworth Campus

Residency

Mayo School of Graduate Medical Education

Fellowship

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine - Oncology

Hospitals & Clinics

Mayo Clinic Rochester

Languages: English/Spanish

507-284-2511

200 S. W. First Street

Rochester, Minnesota 55905

Read More

Publications

Dr. Jan Buckner has contributed to 5 publications.

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas.

Korfiatis, P.,Kline, T. L.,Coufalova, L.,Lachance, D. H.,Parney, I. F.,Carter, R. E.,Buckner, J. C.,Erickson, B. J.; Med Phys.

See more >>

Pragmatic study designs for older adults with cancer: Report from the U13 conference.

Nipp, R. D.,Yao, N. A.,Lowenstein, L. M.,Buckner, J. C.,Parker, I. R.,Gajra, A.,Morrison, V. A.,Dale, W.,Ballman, K. V.; J Geriatr Oncol.

See more >>

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

Brown, P. D.,Anderson, S. K.,Carrero, X. W.,O\'Neill, B. P.,Giannini, C.,Galanis, E.,Shah, S. A.,Abrams, R. A.

See more >>

Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

Berg, A. K.,Buckner, J. C.,Galanis, E.,Jaeckle, K. A.,Ames, M. M.,Reid, J. M.; J Clin Pharmacol

See more >>

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma:

NCCTG N057K. Ma, D. J.,Galanis, E.,Anderson, S. K.,Schiff, D.,Kaufmann, T. J.,Peller, P. J.,Giannini, C.,Brown, P. D.,Uhm, J. H.,McGraw, S.,Jaeck

See more >>

Memberships

American Society of Clinical Oncology